Abstract:Recent studies indicate that synuclein gamma (SNCG) gene, located in chromosome 10, participates in the pathogenesis of the breast and ovary. SNCG, also known as breast cancer-specific gene 1 (BCSG1), is not expressed in normal mammary or ovarian surface epithelial cells but is highly expressed in the vast majority of advanced staged breast and ovarian carcinomas. When overexpressed, SNCG significantly stimulates breast cancer proliferation and metastasis. To fully understand the molecular mechanisms underlying the abnormal expression of SNCG in neoplastic diseases, in this study, we extensively examined the methylation status of a CpG island located in exon 1 of SNCG gene in a panel of breast and ovarian tumor-derived cell lines to determine whether DNA methylation plays a crucial role in SNCG expression. In vivo bisulfite DNA sequencing of genomic DNA isolated from breast cancer cell lines showed that the 15 CpG sites within the CpG island were completely unmethylated in all SNCG-positive cell lines (5 of 5), but were densely and heterogeneously methylated in the majority of SNCG-negative cell lines (3 of 4). The methylation occurred primarily at the CpG sites 2, 5, 7, and 10-15. Similarly, we observed a strong correlation of hypomethylation of the CpG island and SNCG expression in ovarian cancer cell lines (5 of 5). Intriguingly, the methylation pattern in ovarian cancer cells is different from that in breast cancer cells. In SNCG-nonexpressing ovarian cancer cells, all 15 of the CpG sites were completely methylated instead of selective methylation at certain sites shown in breast cancer cells, thereby suggesting a tissue-specific methylation pattern. A correlation between hypomethylation of the exon 1 and expression of SNCG mRNA was also observed in primary breast tumor tissues. The importance of DNA methylation in the control of SNCG expression in cancer cells is further strengthened by demonstration of re-expression of SNCG mRNA in SNCG-negative ovarian and breast cancer cells with a demethylating agent 5-aza-2'-deoxycytidine. In addition, we demonstrate that inhibition of cell growth leads to a decreased mRNA expression and an increased DNA methylation of SNCG gene. Taken together, these new findings strongly suggest that DNA hypomethylation is a common mechanism underlying the abnormal expression of this candidate oncogene in breast and ovarian carcinomas.

Molecular mechanisms for aberrant expression of the human breast cancer specific gene 1 in breast cancer cells: control of transcription by DNA methylation and intronic sequences

Regulatory mechanisms for abnormal expression of the human breast cancer specific gene 1 in breast cancer cells

PGAM1 Regulation of ASS1 Contributes to the Progression of Breast Cancer Through the Camp/ampk/cebpb Pathway

BNC1 Promotes Spermatogenesis by Regulating Transcription of Ybx2 and Papolb Via Direct Binding to Their Promotor Elements

Hypomethylation of the Synuclein Gamma Gene CpG Island Promotes Its Aberrant Expression in Breast Carcinoma and Ovarian Carcinoma.

Blockade of AP1 Transactivation Abrogates the Abnormal Expression of Breast Cancer-specific Gene 1 in Breast Cancer Cells*

Effects of the Methylation Levels for the Breast Cancer Associated Genes BCSG1 and BRCA1 on Cellular Proliferation and Migration

N1-methyladenosine methylation in mRNAs drives bladder cancer progression

BRCA1 Affects Global DNA Methylation Through Regulation of DNMT1

Epigenetic Inactivation of Bcl6b, A Novel Functional Tumour Suppressor for Gastric Cancer, is Associated with Poor Survival

Elevated transcription and glycosylation of B3GNT5 promotes breast cancer aggressiveness

Breast Cancer Epigenetics: From DNA Methylation to microRNAs

Aberrant promoter hypermethylation inhibits RGMA expression and contributes to tumor progression in breast cancer

Discovered Key CpG Sites by Analyzing DNA Methylation and Gene Expression in Breast Cancer Samples

DNA Methyltransferase 1 and 3B Activate BAG-1 Expression Via Recruitment of CTCFL/BORIS and Modulation of Promoter Histone Methylation.

Epigenetic Inactivation of Betaig-h3 Gene in Human Cancer Cells.

Breast Cancer Metastasis Suppressor 1 Modulates SIRT1-dependent P53 Deacetylation Through Interacting with DBC1.

Genetic and Epigenetic Silencing of the Beclin 1 Gene in Sporadic Breast Tumors

CpG hypermethylation of collagen type I alpha 2 contributes to proliferation and migration activity of human bladder cancer

E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter

Expression of Breast Cancer Metastasis Suppressor-1, BRMS-1, in Human Breast Cancer and the Biological Impact of BRMS-1 on the Migration of Breast Cancer Cells.